Equatorial Guinea vs Ukraine: Average cost of drugs for extensively drug-resistant tuberculosis
Equatorial Guinea
1,500 constant 2022 US$
in 2024
Ukraine
1,566 constant 2022 US$
in 2024
Equatorial Guinea rank
33rd
Ukraine rank
31st
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Equatorial Guinea
- Ukraine
How they compare
Ukraine currently reports 1,566 constant 2022 US$ against 1,500 constant 2022 US$ in Equatorial Guinea, a difference of 66 constant 2022 US$.
Across all 6 years both countries report, Ukraine has been ahead every year.
Equatorial Guinea ranks 33rd and Ukraine ranks 31st of 56 countries.
Ukraine has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Equatorial Guinea | Ukraine | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 4,000 constant 2022 US$ | 5,296 constant 2022 US$ | 1,296 constant 2022 US$ | Ukraine |
| 2020s | 2,301 constant 2022 US$ | 3,686 constant 2022 US$ | 1,385 constant 2022 US$ | Ukraine |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Equatorial Guinea or Ukraine?
- Ukraine, at 1,566 constant 2022 US$ against 1,500 constant 2022 US$ in Equatorial Guinea as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Equatorial Guinea and Ukraine?
- 66 constant 2022 US$, with Ukraine ahead.
- How many years of comparable data are there for Equatorial Guinea and Ukraine?
- 6 years are reported by both, from 2019 to 2024.
- How do Equatorial Guinea and Ukraine rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Equatorial Guinea ranks 33rd and Ukraine ranks 31st of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.